Reaktion #351

ord-64de42ce56244836b512746d4c6a3fee

Reaktionsgleichung

N#CCN1Cc2ccc(Cl)nc2O[C@H](c2ccccc2)C1
N#CCN1Cc2ccc(Cl)nc2O
COc1cc(N)ccc1-n1cnc(C)c1
COc1cc(N)ccc1-n1cnc(
COc1cc(Nc2ccc3c(n2)O[C@H](c2ccccc2)CN(CC#N)C3)ccc1-n1cnc(C)c1
COc1cc(Nc2ccc3c(n2)O
Ausbeute 7.8%

Lösungsmittel

Reaktionsbedingungen

Temperatur
100°CELSIUS

Vorschrift

3-methoxy-4-(4-methyl-1H-imidazol-1-yl)aniline (195 mg, 0.96 mmol), (R)-2-(8-chloro-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)acetonitrile (288 mg, 0.96 mmol) Palladium acetate (21.55 mg, 0.10 mmol) and Cesium carbonate (938 mg, 2.88 mmol) were added in a microwave vial. The mixture was capped and flushed with argon. 1,2-dimethoxyethane (5 mL) was added, the reaction mixture was flushed with argon and the mixture was run in a microwave for 60 minutes at 100°C. Only after two additional additions of catalyst and ligand with 3h extra runtime was the reaction complete. The reaction mixture was filtrated through Celite and washed with dichloromethane. The filtrate was concentrated and the crude product was purified by preparative chromatography 3 times yielding (R)-2-(8-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenylamino)-2-phenyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-4(5H)-yl)acetonitrile (35.0 mg, 7.81 %).

Quelle

750 AstraZeneca ELN dataset